asa guidelines for glp-1 drugs glp 1 2025 asa guidelines glp 1 April 2024 Infographic in Anesthesiology-bsmoothhr How should we approach patients
Description
[DOI] [PubMed] [Google Scholar] [98].Henry RR, Rosenstock J, Logan D, Alessi T, Luskey K, Baron MA, Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes, Journal of diabetes and its complications, 28 (2014) 393398
Whereas clinical studies using physiological doses of glucagon did not find elevation in plasma FFAs in humans 44 , supraphysiological glucagon administration increased FFA concentration 45
Tang B, Sjlander A, Wastesson JW, et al
Why GLP-1 Is the Buzzword of 2025 From TikTok influencers to international obesity summits, GLP-1 is everywhere
A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin
